| Jun 21 |
Tevogen Bio files to sell 42.5M shares, plans to offer shares and warrants for holders
|
| Jun 18 |
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
|
| Jun 12 |
Tevogen Bio Set to Join Russell 3000® Index
|
| Jun 11 |
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
|
| Jun 7 |
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
|
| Jun 6 |
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
|
| Jun 6 |
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
|
| May 16 |
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
|
| May 10 |
Tevogen Bio secures up to $50M in financing
|
| May 10 |
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
|
